Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
Total Receivables
Replimune Group Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Replimune Group Inc
NASDAQ:REPL
|
Total Receivables
$4.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Replimune Group Inc's Total Receivables?
Total Receivables
4.9m
USD
Based on the financial report for Mar 31, 2024, Replimune Group Inc's Total Receivables amounts to 4.9m USD.
What is Replimune Group Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
15%
Over the last year, the Total Receivables growth was 70%. The average annual Total Receivables growth rates for Replimune Group Inc have been 18% over the past three years , 15% over the past five years .